Dye incubation was carried out on HepaRG cells, on CML cell lines K562, BV173, and KCL22, as well as on the AML cell lines MV4-11, MOLM13, HL60, and M07e. DY-736, DY-615, and DY-630 showed no significant difference between CML and AML cell lines (RFU DY-736 18.3 ± 1.5 ...
Histone deacetylases inhibitor (HDACi) has displayed excellent anti-tumor activity both in CML and AML [12,13]. Previous studies have demonstrated that pan-HDACi (Panobinostat, the most active HDACi) alone partially removed quiescent primitive LSCs while the combination of TKI and HDACi markedly ...
While the GVL effect is potent against chronic phase (CP) CML, it is less effective against blast crisis (BC) CML and AML. To better understand this difference we have been studying GVL against mouse models of CP-CML (mCP-CML) and BC-CML (mBC-CML) induced by infecting bone marrow (...
For instance, targeting amino acid metabolism, fatty acid oxidation, or glutaminolysis along with the standard treatment eliminates AML LSCs [19,20,21]. While in T cell acute lymphoblastic leukemia, treatment modifies cellular metabolism from glutaminolysis to glycolysis to evade drug-induced cellular ...
Sample exchange typically involves testing around 30 CML patient samples spanning the range from MR2-MR4.5 (i.e., 2–4.5 logs below the IRIS standardized baseline) in both an established reference laboratory and a test laboratory followed by calculation of the mean difference by Bland–Altman anal...
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 and PD-L1 inhibitors. February 15th 2025 Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302 Mary Caffrey The lead investigat...
After adjusting for MCyR, the difference in MMR rate between treatment arms was 12.2% (95% CI, 2.19-22.30; P = .029). In terms of safety, fewer grade 3 or higher adverse events (AEs) (50.6% vs 60.5%) and AEs leading to treatment discontinuation (5.8% vs 21.1%) occurred ...
“[In previously reported data] there is a similar benefit of asciminib compared with bosutinib at 24 weeks and at 48 weeks, and the difference has actually increased in favor of asciminib at the 96-week [landmark],” Jorge E. Cortes, MD director of the Georgia Cancer Center in Atlan...
Breaking Down T-Cell Therapies: TCR and CAR T Mechanisms Therapies With Different Mechanisms of Action Available for Low-Risk MDS Merryman Discusses the Role of MRD in Lymphoma Care and Trials Erba Explores myeloMATCH Substudies Targeting Genetic Diversity in AML, MDS Ring Sideroblasts Status Affec...
This difference was significant by the Fisher exact test (2-sided; P = .047). When broken into individual MPD diagnoses, the prevalence of the JAK2 mutation in 9 AML patients with antecedent PV was lower (5 [56%] of 9 patients) than in the total group of PV patients studied (25 [...